- Published on
Ophthalmology – Choroidal Neovascularization
Choroidal neovascularization (CNV) refers to the formation of abnormal new blood vessels originating from the choroid that penetrate through defects in Bruch’s membrane into the subretinal space. These vessels often form a fibrovascular complex that is fragile and prone to leakage, leading to accumulation of fluid, lipid exudation, and hemorrhage. Over time, this process can result in the formation of a disciform scar and permanent vision loss. CNV is not a standalone disease but a complication of many underlying disorders affecting the retinal pigment epithelium (RPE)–Bruch’s membrane–choriocapillaris complex.
Epidemiologically, the incidence and prevalence of CNV vary depending on the underlying condition. It is most commonly associated with age-related macular degeneration (AMD), which is the leading cause of irreversible vision loss in individuals over 65 years in developed countries. Advanced AMD affects tens of millions of people worldwide. The likelihood of developing CNV increases significantly with age and is influenced by systemic and genetic factors.
Risk factors depend largely on the underlying disease. In AMD-related CNV, advancing age, smoking, hypertension, hyperlipidemia, obesity, and reduced physical activity play significant roles. A strong family history also increases risk, reflecting a genetic predisposition. Genetic studies, including twin studies and genome-wide analyses, support the multifactorial inheritance pattern of AMD and its complications such as CNV.
The pathophysiology involves disruption of Bruch’s membrane, which allows neovascular tissue from the choriocapillaris to grow into the subretinal space. This process is driven by proangiogenic factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor, and other inflammatory mediators. CNV can be classified based on its location relative to the RPE, including type 1 (sub-RPE), type 2 (subretinal), or mixed forms.
Clinically, patients typically present with sudden onset of decreased central vision, often accompanied by metamorphopsia and paracentral scotomas. On examination, findings may include RPE elevation, subretinal fluid, lipid exudates, hemorrhage, and a gray-green lesion beneath the retina. These features reflect the leakage and instability of the neovascular membrane.
Diagnosis is primarily made using imaging techniques. Fluorescein angiography helps identify leakage patterns and differentiate between classic and occult CNV. Optical coherence tomography (OCT) is essential for detecting structural changes such as subretinal fluid, intraretinal edema, and RPE detachment, and is also useful for monitoring response to treatment.
Management has evolved significantly with the advent of anti-VEGF therapy, which is now the standard of care. Intravitreal injections of agents such as ranibizumab or bevacizumab inhibit neovascular growth and reduce leakage, often stabilizing or improving vision. In selected cases, particularly extrafoveal lesions or non-AMD etiologies, laser photocoagulation or photodynamic therapy may be considered. Surgical options such as vitrectomy are reserved for complications like submacular hemorrhage.
The prognosis depends on the location of the lesion and the extent of damage at presentation. Early detection and treatment significantly improve visual outcomes. However, recurrence is common, requiring ongoing monitoring with tools such as the Amsler grid and serial imaging.
Complications include subretinal fibrosis, persistent or recurrent fluid accumulation, and, in severe cases, massive subretinal hemorrhage that can lead to retinal detachment and profound vision loss.
- Published on
Ophthalmology – Choroidal Nevus
Choroidal nevus is the most common intraocular tumor and represents a benign melanocytic lesion arising within the uveal tract, most commonly in the choroid. It typically appears as a pigmented (brown in about 80% of cases) or less commonly nonpigmented lesion. Most nevi are small, measuring approximately 2 mm in diameter and 1.5 mm in thickness, and may be associated with overlying retinal pigment epithelium (RPE) changes such as drusen, hyperplasia, or atrophy. Although benign, careful evaluation is essential to differentiate it from choroidal melanoma.
Epidemiologically, choroidal nevus is far more common in Caucasians, particularly those with blue eyes. The overall prevalence is estimated to be around 7% in Caucasian adults, with increasing detection rates with age. Although believed to be present from birth, most nevi are identified later in life when pigmentation develops or during routine dilated fundus examinations. It affects both genders equally, though some studies suggest a slight female predominance.
Risk factors primarily include fair skin and light-colored eyes, reflecting a predisposition in individuals with less ocular pigmentation. There is no known hereditary pattern or genetic predisposition, and no established method of prevention. The exact pathophysiology and etiology remain unknown, although it is considered a benign proliferation of melanocytes within the choroid.
Most patients with a choroidal nevus are asymptomatic, with approximately 84% having no visual complaints. A minority may experience decreased vision, flashes, floaters, or visual field defects depending on the lesion’s location, particularly if it involves the macula. On examination, the lesion appears as a flat or minimally elevated pigmented area, commonly located outside the fovea.
Diagnosis is primarily clinical, supported by multimodal imaging. Fundus photography helps document size and location, while ultrasonography assesses thickness. Optical coherence tomography (OCT) is useful for detecting subretinal fluid or retinal changes overlying the nevus. Fluorescein and indocyanine green angiography can evaluate vascular characteristics, and autofluorescence imaging helps assess RPE health. These tools are also critical for monitoring stability over time.
A key aspect of management is distinguishing benign nevi from lesions at risk of malignant transformation. Risk factors suggesting possible progression to melanoma can be remembered with the mnemonic “To Find Small Ocular Melanoma Using Helpful Hints Daily,” which includes thickness greater than 2 mm, subretinal fluid, symptoms, orange pigment, proximity to the optic disc, ultrasound hollowness, absence of halo, and absence of drusen. Lesions with multiple risk factors warrant closer observation or referral.
There is no medical treatment for choroidal nevus. Management typically consists of observation with periodic follow-up every 3–6 months initially, then biannually if stable. Imaging is repeated to detect any growth or development of suspicious features. Intervention is considered only if there is documented growth or complications such as subretinal fluid affecting vision, which may prompt treatments similar to those used for melanoma.
The prognosis is excellent for stable lesions without growth. Visual outcome depends largely on location; extrafoveal lesions usually preserve vision, whereas subfoveal nevi may lead to visual decline. The main complication is rare transformation into choroidal melanoma, as well as potential vision loss if the lesion affects the macula.
- Published on
Ophthalmology – Choroidal Rupture
Choroidal rupture is a traumatic break involving the choroid, Bruch’s membrane, and the retinal pigment epithelium (RPE), typically resulting from blunt ocular trauma. The injury occurs when the globe is rapidly compressed and then expands, causing mechanical stress that exceeds the tensile strength of Bruch’s membrane. While the sclera and retina are relatively elastic and resistant, Bruch’s membrane is more brittle and prone to tearing.
Epidemiologically, blunt ocular trauma is the most common type of eye injury, and approximately 5–10% of such cases result in choroidal rupture. Most patients have a single rupture, although multiple ruptures can occur in up to 25% of cases. The majority are located temporal to the optic disc, and about two-thirds involve the macula. Although rare in the general population, choroidal rupture is more frequently encountered in individuals with a history of ocular trauma.
The primary risk factor is blunt trauma to the eye, often occurring in younger individuals, particularly males. Patients with pre-existing abnormalities of Bruch’s membrane, such as angioid streaks, are more susceptible and may develop ruptures even after relatively minor trauma. Preventive measures include the use of protective eyewear, especially during contact sports or high-risk activities.
Pathophysiologically, trauma causes rupture of Bruch’s membrane and damage to the underlying choriocapillaris, leading to subretinal or sub-RPE hemorrhage. In the acute phase, hemorrhage and retinal edema may obscure the rupture. As the hemorrhage resolves, the rupture becomes visible as a characteristic white, curvilinear streak, often concentric to the optic disc. Choroidal ruptures are classified as direct (at the site of impact) or indirect (away from the impact site, typically in the posterior pole).
Clinically, patients usually present with a history of blunt trauma followed by decreased vision, central or paracentral scotoma, or visual distortion. On examination, findings may include subretinal hemorrhage and, later, the classic crescent-shaped streak. Additional traumatic findings such as retinal tears, macular holes, or retinal detachment may also be present and should be actively sought.
Diagnosis is primarily clinical but supported by imaging. Fluorescein angiography typically shows an early hypofluorescent streak followed by late hyperfluorescence. Indocyanine green angiography can help identify ruptures obscured by hemorrhage. Optical imaging and B-scan ultrasonography may assist in evaluating associated complications. CT imaging may be required if there is concern for orbital fractures or intraocular foreign bodies.
There is no direct treatment for the rupture itself. Management focuses on identifying and treating associated injuries and complications. Inflammation may be treated with topical steroids and cycloplegics. A key long-term complication is choroidal neovascularization (CNV), which may develop months to years later and is typically treated with anti-VEGF therapy.
Prognosis depends largely on the location of the rupture. Subfoveal ruptures are associated with poor visual outcomes, whereas extrafoveal ruptures often preserve good vision unless complicated by CNV. Many patients do not achieve visual acuity better than 20/40, particularly if the macula is involved.
Complications include CNV (the most common late complication), retinal detachment, and persistent visual field defects. Patients should be monitored closely over time and educated to use tools such as an Amsler grid to detect early visual changes suggestive of CNV development.
Ophthalmology – Choroidal Rupture
Choroidal rupture is a traumatic break involving the choroid, Bruch’s membrane, and the retinal pigment epithelium (RPE), typically resulting from blunt ocular trauma. The injury occurs when the globe is rapidly compressed and then expands, causing mechanical stress that exceeds the tensile strength of Bruch’s membrane. While the sclera and retina are relatively elastic and resistant, Bruch’s membrane is more brittle and prone to tearing.
Epidemiologically, blunt ocular trauma is the most common type of eye injury, and approximately 5–10% of such cases result in choroidal rupture. Most patients have a single rupture, although multiple ruptures can occur in up to 25% of cases. The majority are located temporal to the optic disc, and about two-thirds involve the macula. Although rare in the general population, choroidal rupture is more frequently encountered in individuals with a history of ocular trauma.
The primary risk factor is blunt trauma to the eye, often occurring in younger individuals, particularly males. Patients with pre-existing abnormalities of Bruch’s membrane, such as angioid streaks, are more susceptible and may develop ruptures even after relatively minor trauma. Preventive measures include the use of protective eyewear, especially during contact sports or high-risk activities.
Pathophysiologically, trauma causes rupture of Bruch’s membrane and damage to the underlying choriocapillaris, leading to subretinal or sub-RPE hemorrhage. In the acute phase, hemorrhage and retinal edema may obscure the rupture. As the hemorrhage resolves, the rupture becomes visible as a characteristic white, curvilinear streak, often concentric to the optic disc. Choroidal ruptures are classified as direct (at the site of impact) or indirect (away from the impact site, typically in the posterior pole).
Clinically, patients usually present with a history of blunt trauma followed by decreased vision, central or paracentral scotoma, or visual distortion. On examination, findings may include subretinal hemorrhage and, later, the classic crescent-shaped streak. Additional traumatic findings such as retinal tears, macular holes, or retinal detachment may also be present and should be actively sought.
Diagnosis is primarily clinical but supported by imaging. Fluorescein angiography typically shows an early hypofluorescent streak followed by late hyperfluorescence. Indocyanine green angiography can help identify ruptures obscured by hemorrhage. Optical imaging and B-scan ultrasonography may assist in evaluating associated complications. CT imaging may be required if there is concern for orbital fractures or intraocular foreign bodies.
There is no direct treatment for the rupture itself. Management focuses on identifying and treating associated injuries and complications. Inflammation may be treated with topical steroids and cycloplegics. A key long-term complication is choroidal neovascularization (CNV), which may develop months to years later and is typically treated with anti-VEGF therapy.
Prognosis depends largely on the location of the rupture. Subfoveal ruptures are associated with poor visual outcomes, whereas extrafoveal ruptures often preserve good vision unless complicated by CNV. Many patients do not achieve visual acuity better than 20/40, particularly if the macula is involved.
Complications include CNV (the most common late complication), retinal detachment, and persistent visual field defects. Patients should be monitored closely over time and educated to use tools such as an Amsler grid to detect early visual changes suggestive of CNV development.
- Published on
Ophthalmology – Choroideremia
Choroideremia is a rare, progressive, X-linked inherited retinal disorder characterized by degeneration of the retinal pigment epithelium (RPE), choroid, and photoreceptors. It primarily affects males, while female carriers are usually asymptomatic or exhibit only mild findings. The disease leads to gradual vision loss over decades, eventually resulting in blindness.
Epidemiologically, choroideremia has an estimated prevalence of approximately 1 in 50,000 individuals. Because it is inherited in an X-linked recessive pattern, it predominantly affects males with a positive family history. Female carriers may occasionally show mild retinal changes but rarely develop significant visual impairment.
The underlying genetic defect involves mutations in the CHM gene located on the X chromosome (Xq21.2). This gene encodes the Rab escort protein (REP-1), which is essential for intracellular vesicle transport and normal RPE function. Loss of REP-1 disrupts cellular processes such as phagocytosis of photoreceptor outer segments, lysosomal activity, and intracellular trafficking. These abnormalities ultimately lead to progressive degeneration of the RPE, followed by secondary loss of photoreceptors and choroidal structures.
Clinically, affected males typically present with night blindness (nyctalopia), often beginning in childhood or adolescence. This is followed by progressive peripheral vision loss, initially manifesting as annular scotomas and eventually leading to concentric visual field constriction. By around 40 years of age, many patients have severe peripheral vision loss approaching legal blindness, although central visual acuity is often preserved until later in life.
On examination, early fundus findings include pigmentary changes and patchy areas of RPE and choroidal atrophy in the mid-periphery. As the disease progresses, these areas coalesce, exposing the underlying sclera and leaving only small islands of functioning retina, typically around the macula and optic disc. In advanced stages, the retina appears markedly thinned with extensive choroidal loss.
Diagnosis is primarily clinical but can be confirmed with genetic testing. Functional testing such as visual field analysis and electroretinography (ERG) is useful for assessing disease severity and progression. ERG initially shows a rod-cone degeneration pattern and eventually becomes non-recordable in advanced disease. Imaging modalities such as fluorescein angiography may demonstrate areas of capillary non-perfusion corresponding to atrophic regions.
There is currently no definitive treatment for choroideremia. Management focuses on monitoring disease progression and supportive care. Emerging therapies, particularly gene therapy aimed at restoring REP-1 function, show promise but remain under investigation. Patients may benefit from low vision rehabilitation as visual function declines. Protective measures such as UV-blocking sunglasses may help reduce additional retinal stress.
Genetic counseling is an essential component of care, given the X-linked inheritance pattern. Families should be educated about transmission risks, including the 50% chance of carrier mothers passing the mutation to offspring. Prenatal testing may be considered in affected families.
The prognosis involves progressive visual decline. Most affected males develop severe peripheral vision loss by midlife and eventual loss of central vision later in life, leading to blindness. Female carriers generally have a much milder course.
Complications primarily relate to progressive vision loss and its functional consequences, including reduced independence and quality of life. Posterior subcapsular cataracts may also develop in some patients and can be managed surgically if needed.
- Published on
Ophthalmology – Choroidal Folds
Choroidal folds are parallel striae seen at the posterior pole of the eye and may be oriented horizontally, vertically, or obliquely. They are not a disease themselves but rather a clinical sign that can be idiopathic or associated with a variety of ocular, orbital, or systemic conditions. Their presence should always prompt evaluation for an underlying cause.
The exact epidemiology of choroidal folds is unknown. They may occur in a wide range of patients depending on the associated underlying condition. Since they are often asymptomatic, many cases may go undetected unless identified during routine fundus examination.
The pathophysiology involves wrinkling of the retinal pigment epithelium (RPE), Bruch’s membrane, and inner choroidal layers. This is believed to result from an imbalance between forces acting on the globe. These forces may be internal, such as hypotony, or external, such as orbital masses or increased intracranial pressure. Direct tractional forces, for example from choroidal neovascular membranes, can also contribute. The characteristic appearance of alternating light and dark bands reflects structural changes in the RPE and choroid.
Etiologically, many cases are idiopathic, but secondary causes are common and must be considered. Ocular causes include choroidal tumors, neovascularization, inflammation, hypotony, posterior scleritis, uveal effusion, central serous chorioretinopathy, and prior scleral buckle surgery. Optic nerve-related causes include papilledema and optic nerve tumors. Orbital conditions such as tumors, inflammation, or thyroid eye disease may also lead to folds. Additionally, increased intracranial pressure alone can produce choroidal folds, even in the absence of papilledema.
Clinically, patients may be asymptomatic or may report blurred vision or metamorphopsia. On funduscopic examination, choroidal folds appear as alternating light (yellow) and dark (orange) parallel lines at the posterior pole. A comprehensive ocular examination, including intraocular pressure measurement, is essential to help identify any underlying pathology.
Diagnostic imaging plays an important role. Fluorescein angiography typically demonstrates an alternating pattern of hyperfluorescence and hypofluorescence corresponding to stretched and compressed areas of the RPE. Optical coherence tomography (OCT) can clearly show undulations of the RPE and helps differentiate choroidal folds from retinal folds. Fundus autofluorescence may also provide supportive findings. If an underlying cause is suspected, further orbital imaging such as B-scan ultrasonography, CT, or MRI may be required.
Management of choroidal folds is directed toward treating the underlying cause. In cases where no cause is identified and the patient is asymptomatic, observation with periodic follow-up is appropriate. Serial fundus examinations are recommended to monitor for changes or the emergence of an underlying condition.
- Published on
Ophthalmology – Clinically Significant Diabetic Macular Edema (CSME)
Clinically significant diabetic macular edema (CSME) is a vision-threatening form of diabetic macular edema defined by the Early Treatment Diabetic Retinopathy Study (ETDRS). It is present when there is retinal thickening within 500 microns of the center of the fovea, hard exudates within 500 microns of the foveal center with adjacent retinal thickening, or an area of retinal thickening at least one disc area in size with any part located within one disc diameter of the foveal center. CSME may be focal, resulting from leakage from isolated microaneurysms, or diffuse, due to generalized breakdown of the inner blood-retinal barrier.
CSME is the leading cause of visual loss in patients with diabetes. Its frequency increases with longer duration of diabetes and with more severe diabetic retinopathy. Studies have shown that a substantial proportion of both type 1 and type 2 diabetic patients develop CSME over time, and hundreds of thousands of individuals are affected in the United States alone.
Major risk factors include long-standing diabetes, poor glycemic control, hypertension, hyperlipidemia, nephropathy, proteinuria, and more advanced diabetic retinopathy. In patients with adult-onset diabetes, insulin use has also been associated with higher risk. Pregnancy can accelerate diabetic retinopathy and CSME, so careful ophthalmic monitoring is recommended before and throughout pregnancy.
The pathophysiology of CSME reflects chronic hyperglycemia-induced damage to the retinal microvasculature. This includes pericyte loss, thickening of the capillary basement membrane, endothelial dysfunction, leukostasis, oxidative stress, and increased inflammatory cytokines such as VEGF. These changes lead to breakdown of the blood-retinal barrier and leakage of fluid into the macula. In some cases, vitreomacular traction may also contribute to edema formation.
Patients may not always notice symptoms early, but a careful history should assess diabetes duration and control, insulin dependence, hypertension, lipid disorders, and kidney disease. Clinically, CSME is diagnosed by slit-lamp biomicroscopy, sometimes aided by contact lens examination, which demonstrates retinal thickening in the macular area. The severity of diabetic retinopathy and the presence of vitreomacular interface abnormalities should also be documented.
Ancillary testing is helpful for both evaluation and follow-up. Fluorescein angiography is not necessary to make the diagnosis, but it can identify leaking microaneurysms, diffuse leakage, areas of macular ischemia, and capillary nonperfusion. Optical coherence tomography (OCT) is especially valuable for documenting retinal thickening, identifying epiretinal membranes or vitreomacular traction, and monitoring treatment response. Systemic evaluation should include HbA1c, blood pressure, blood lipids, and renal function.
Treatment begins with optimization of systemic disease, including strict control of blood glucose, blood pressure, and lipids. Traditionally, focal laser photocoagulation has been the first-line ocular treatment and has been shown to reduce the risk of visual loss substantially. More recently, intravitreal anti-VEGF agents such as ranibizumab and bevacizumab have become important options and may be superior to laser alone in many cases. Intravitreal corticosteroids can also be useful, especially in selected patients, though they are generally considered adjunctive therapy.
In cases of diffuse CSME, refractory edema, or associated vitreomacular traction, referral to a vitreoretinal specialist is appropriate. Vitrectomy with membrane peeling may benefit patients with persistent edema related to traction or epiretinal membrane formation. Fenofibrate may also reduce the need for laser in some diabetic patients.
Close follow-up is essential because CSME is often chronic and recurrent. Patients undergoing active treatment are commonly reviewed every 1 to 3 months, and those with severe nonproliferative or proliferative diabetic retinopathy generally require dilated examination every 3 to 4 months. Coordination with the patient’s primary care physician or endocrinologist is an important part of management.
The prognosis depends on the duration and severity of edema, associated retinal ischemia, and response to treatment. Without treatment, many patients experience moderate visual loss over time. Laser therapy significantly lowers this risk, and newer therapies may further improve outcomes.
- Published on
Ophthalmology – Congenital and Infantile Glaucoma
Congenital and infantile glaucoma is a developmental disorder characterized by trabeculodysgenesis, leading to impaired aqueous humor outflow and elevated intraocular pressure (IOP). It presents at birth or within the first 3–4 years of life and must be distinguished from secondary pediatric glaucomas associated with other ocular or systemic conditions.
The condition may be unilateral (25%) or bilateral (75%), and early recognition is critical to prevent permanent visual damage.
Epidemiologically, incidence varies by region. It is more common in certain populations (e.g., parts of the Middle East) and relatively rare in the United States. There is a slight male predominance (3:2), and family history is an important risk factor.
Genetically, about 10% of cases follow an autosomal recessive inheritance pattern. Several loci have been identified, most notably mutations in the CYP1B1 gene. Other genes such as MYOC and LTBP2 may also be involved. Genetic counseling is recommended, especially in familial cases.
Pathophysiologically, abnormal development of the anterior chamber angle structures leads to impaired aqueous drainage. Proposed mechanisms include malformed trabecular meshwork, abnormal insertion of the iris or ciliary body, and abnormalities of Schlemm’s canal. These abnormalities result in increased intraocular pressure, which in infants causes stretching of ocular tissues.
The classic clinical triad includes:
• Epiphora (excessive tearing)
• Photophobia (light sensitivity)
• Blepharospasm (eyelid squeezing)
Additional features include enlarged eyes (buphthalmos), cloudy corneas, and progressive myopia. Corneal enlargement (>12 mm in diameter) and breaks in Descemet’s membrane known as Haab’s striae are characteristic findings.
Examination often requires sedation or anesthesia. Key findings include elevated IOP (typically 25–35 mm Hg), increased axial length, corneal edema, and optic nerve cupping. Unlike adult glaucoma, optic nerve changes in children may be partially reversible if treated early.
Diagnostic evaluation includes tonometry, gonioscopy (to assess angle structures), optic nerve imaging, and sometimes optical coherence tomography. Visual field testing is performed later when the child is developmentally able.
The differential diagnosis includes other causes of tearing (such as nasolacrimal duct obstruction), corneal clouding (e.g., dystrophies, infections), and enlarged cornea (e.g., megalocornea).
Management is primarily surgical, as this is a structural problem. Medical therapy is used only as a temporary or adjunctive measure to lower IOP. First-line medications include topical beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogues. Alpha-2 agonists (like brimonidine) should be avoided in very young children due to risk of central nervous system depression.
The mainstay of treatment is angle surgery:
• Goniotomy – first-line in clear corneas, with ~80% success
• Trabeculotomy – preferred when the cornea is cloudy
If these fail, further options include tube shunts, trabeculectomy, or cyclophotocoagulation in advanced cases.
Supportive care is equally important. This includes correction of refractive errors, treatment of strabismus, and especially prevention of amblyopia, which is the most common cause of visual loss in these patients. Frequent refraction and visual monitoring are essential.
Lifelong follow-up is required. Infants often need examinations every 3–4 months, including periodic exams under anesthesia. Monitoring focuses on IOP control, corneal clarity, optic nerve status, and visual development.
Prognosis depends on early diagnosis and timely surgical intervention. Approximately 80% of patients achieve adequate IOP control, and about 40% may retain good visual acuity (20/40 or better). Outcomes are generally better when surgery is performed between 2–12 months of age.
Complications include visual field loss, amblyopia, refractive errors (myopia, astigmatism), cataract, corneal scarring, and blindness. In severe or untreated cases, the eye may become painful or progress to phthisis bulbi.
- Published on
Ophthalmology – Cone Dystrophy
Cone dystrophy is a progressive retinal disorder characterized by degeneration of cone photoreceptors, leading to the classic triad of central vision loss, photophobia, and dyschromatopsia (color vision impairment). It represents a heterogeneous group of inherited conditions with variability in clinical presentation and genetic causes.
Cone disorders exist along a spectrum. At one end are cone dysfunction syndromes (such as Achromatopsia), which present early in life and are non-progressive. At the other end are cone dystrophies, which are progressive and typically present from childhood to early adulthood. A related group, cone-rod dystrophies, involves both cone and rod degeneration early in the disease course.
The prevalence of cone dystrophy is approximately 1 in 40,000 individuals. A positive family history is a significant risk factor. Although many cases are sporadic, inheritance patterns include autosomal dominant (most common), autosomal recessive, and X-linked recessive forms.
The underlying pathophysiology involves primary degeneration of cone photoreceptors. Because cones are responsible for central vision and color perception, symptoms often appear before any visible retinal changes. All three cone subtypes (responsible for different color wavelengths) are affected, leading to generalized color vision deficits that may progress to complete color blindness. Over time, some patients may also develop secondary rod involvement.
Patients usually present before the age of 20 with progressive decrease in visual acuity, marked photophobia, and early color vision abnormalities. Difficulty distinguishing colors is often one of the earliest signs. If night blindness (nyctalopia) becomes prominent along with these symptoms, a cone-rod dystrophy should be suspected instead.
On examination, findings can be highly variable. The fundus may initially appear normal, especially early in the disease. As the condition progresses, changes may include subtle macular granularity or a characteristic bull’s-eye maculopathy, where a central area of relative preservation is surrounded by a ring of retinal pigment epithelial atrophy. Visual acuity ranges widely, from normal (20/20) to severe impairment. Optic discs may show temporal pallor in advanced cases.
Color vision testing using tools such as the Farnsworth-Munsell 100-Hue test reveals abnormalities across multiple color axes. Visual field testing often demonstrates central scotomas while peripheral fields are relatively preserved.
The most important diagnostic test is the electroretinogram (ERG). Cone dystrophy shows markedly reduced photopic (cone-mediated) responses with relatively preserved or mildly reduced scotopic (rod-mediated) responses. Optical coherence tomography (OCT) may demonstrate disruption or loss of the photoreceptor layer, particularly at the inner segment–outer segment junction. Fundus autofluorescence may show foveal hyperautofluorescence.
The differential diagnosis includes other macular and retinal disorders such as Stargardt disease, hereditary optic atrophies, toxic maculopathy, and cone-rod dystrophies. Distinguishing features include the early and prominent color vision loss and ERG findings.
There is currently no definitive cure for cone dystrophy. Management is primarily supportive. Red-tinted contact lenses may reduce photophobia and improve visual comfort. Patients often benefit from referral to low vision specialists to optimize remaining vision and maintain quality of life.
Emerging therapies, including gene therapy, stem cell therapy, and photoreceptor transplantation, are under investigation but are not yet standard treatments.
Ongoing care includes periodic monitoring of visual acuity, color vision, and retinal function (via ERG). Genetic counseling is important to help patients understand inheritance patterns and risks to family members.
The prognosis is variable. Earlier onset generally correlates with more severe disease and faster progression. Some patients retain functional vision for many years, while others may develop significant visual impairment or blindness.
Complications primarily include progressive vision loss and complete loss of color vision, which can significantly impact daily functioning and independence.
- Published on
Ophthalmology – Commotio Retinae (Berlin’s Edema)
Commotio retinae, also known as Berlin’s edema when involving the macula, is a retinal condition that occurs following blunt ocular trauma. It is characterized by transient whitening or opacification of the retina due to disruption of the outer retinal layers, particularly the photoreceptors. Despite the term “edema,” the primary pathology is not true fluid accumulation but rather structural damage to retinal cells.
Blunt ocular trauma is relatively common, affecting approximately 4.9 per 1,000 individuals annually. This condition is frequently seen in younger males, especially in the setting of sports-related injuries or high-impact activities. It may also occur during household or occupational accidents involving sudden blunt force to the eye.
The main risk factor is any activity with potential for eye trauma, such as contact sports. Preventive strategies include the use of protective eyewear that meets recognized safety standards, such as ANSI-certified goggles for occupational use and ASTM-approved eyewear for sports.
The pathophysiology involves rapid compression and decompression of the globe (coup–countercoup mechanism), leading to shearing forces that disrupt the photoreceptor outer segments and retinal pigment epithelium. This mechanical injury results in the characteristic retinal whitening seen on examination.
Patients typically present with a history of recent blunt trauma to the eye. Visual symptoms vary depending on the location and extent of retinal involvement. Visual acuity may range from normal (20/20) to significantly reduced (as poor as 20/400), particularly if the macula is involved.
On examination, the retina appears opacified and whitish, often with minimal edema. Retinal vessels usually remain normal in appearance, which helps distinguish this condition from vascular occlusions. In some cases, small retinal or preretinal hemorrhages may be present. A thorough dilated fundus examination with scleral depression is essential to rule out associated injuries.
Commotio retinae is often associated with other ocular injuries from trauma, including subconjunctival hemorrhage, eyelid bruising, hyphema, traumatic iritis, angle recession, orbital fractures, Choroidal rupture, and traumatic macular holes.
Optical coherence tomography (OCT) can be helpful in evaluating the extent of damage, particularly in macular involvement. It typically shows hyperreflectivity and disruption at the level of the photoreceptors and retinal pigment epithelium. Fundus photography can also be used for documentation and follow-up.
The differential diagnosis includes conditions that may also present with retinal whitening, such as Central retinal artery occlusion, branch retinal artery occlusion, shallow retinal detachment, and white-without-pressure. Clinical history and examination findings are key to differentiation.
Management is primarily conservative, as commotio retinae usually resolves spontaneously without specific treatment. Observation is the standard approach. Patients should be re-evaluated by an ophthalmologist within 1 to 2 weeks to ensure resolution and to monitor for complications.
Patient education is important. Individuals should be advised to seek immediate care if they develop symptoms suggestive of retinal tear or detachment, such as flashes, floaters, or a curtain-like loss of vision.
The prognosis is generally favorable, especially in cases where the macula is not involved. Most patients experience full recovery without lasting effects. However, macular involvement may lead to persistent visual impairment.
Potential complications include retinal tears, retinal detachment, macular hole formation, and, in some cases, permanent visual loss.
- Published on
Ophthalmology – Coloboma
Coloboma is a congenital ocular defect characterized by a cleft or gap in ocular structures due to incomplete closure of the embryonic (choroidal) fissure during early fetal development. It may affect the iris, retina, choroid, or optic nerve, and is typically located in the inferonasal quadrant. Coloboma can occur unilaterally or bilaterally and may be isolated or associated with other ocular or systemic abnormalities.
The condition is relatively uncommon, with an estimated incidence of approximately 2.6 per 10,000 births in the United States. While some cases occur in isolation, a significant proportion are associated with other congenital anomalies or syndromes, particularly CHARGE syndrome, which is one of the most frequently linked multisystem conditions.
Risk factors include genetic mutations, chromosomal abnormalities, and environmental influences during pregnancy. Several genes have been implicated, including PAX6, SHH, and CHD7. Coloboma is also associated with Microphthalmia, and potential environmental contributors include teratogens such as alcohol or thalidomide, as well as vitamin A deficiency during pregnancy. Inheritance patterns vary and may be sporadic, autosomal dominant, autosomal recessive, or X-linked.
The underlying pathophysiology involves failure of closure of the fetal fissure between the 5th and 7th weeks of gestation. This results in defective development of the retinal pigment epithelium, abnormal choroidal formation, and dysplastic overlying retina. The timing and extent of this developmental failure influence both the severity of the ocular defect and the likelihood of associated systemic anomalies.
Clinically, presentation depends on the structures involved. Iris coloboma appears as a characteristic “keyhole” pupil, usually inferonasally. Posterior segment involvement, such as chorioretinal coloboma, presents as a sharply demarcated white excavation in the fundus, sometimes with visible retinal vessels traversing the defect. Visual symptoms may include decreased vision, visual field defects (typically superior scotoma), strabismus, or nystagmus. Some patients may present with leukocoria.
A comprehensive examination is essential, including visual acuity testing, slit-lamp evaluation, and dilated fundus examination. Assessment for amblyopia, refractive error, and retinal detachment is critical. Family members may also require examination, as some cases are asymptomatic but hereditary. Systemic evaluation is important to identify associated anomalies.
Diagnostic investigations may include ocular ultrasound to assess for associated cysts or microphthalmia, and brain MRI if optic nerve involvement or central nervous system abnormalities are suspected. Genetic testing and counseling are recommended, particularly in syndromic or familial cases. Additional systemic investigations such as echocardiography or audiology testing may be indicated depending on associated findings.
Management focuses on maximizing visual potential and monitoring for complications, as there is no direct treatment for the structural defect itself. Amblyopia therapy is often required in children. Patients with significant visual impairment may benefit from low vision rehabilitation. Referral to genetics and pediatric specialists is appropriate when systemic associations are present.
Surgical intervention may be necessary for complications such as retinal detachment, cataract, or strabismus. In severe cases with microphthalmia, ocular prosthetic support may be considered for cosmetic and structural purposes.
Regular follow-up is essential, particularly to monitor for retinal detachment, which is a known complication. Visual development, educational progress, and systemic health should also be monitored over time.
The prognosis varies widely depending on the size and location of the defect. Small anterior colobomas may have minimal visual impact, whereas large posterior colobomas involving the macula or optic nerve can result in significant visual impairment. Associated systemic abnormalities further influence overall outcomes.
